肿瘤标志物联合检测在卵巢疾病诊断中的临床价值探讨
|
摘要
目的探讨血清糖类抗原125(CA125)、人附睾蛋白4(HE4)、糖类抗原724(CA72-4)、糖类抗原199(CA19-9)、β2微球蛋白(β2-MG)和铁蛋白(Fer)6项指标在卵巢疾病诊断中的临床价值。方法选取本院2015年6月-2016年12月确诊的卵巢癌患者33例(卵巢癌组)、良性卵巢疾病患者60例(良性卵巢疾病组)以及54例健康女性(对照组),采用化学发光法检测3组人群的CA125、HE4、CA72-4、CA19-9、β2-MG和Fer水平,并进行统计学分析。结果卵巢癌组6项指标均高于良性卵巢疾病组和对照组,差异有统计学意义(P<0.05);卵巢癌组6项指标的阳性率均高于良性卵巢疾病组和对照组,差异有统计学意义(P<0.05);联合检测CA125、HE4、Fer卵巢癌组的阳性率可达97.0%,良性卵巢疾病组的阳性率为30.0%,高于单项检测的阳性率。结论 Fer也是诊断卵巢癌的较好指标,联合检测CA125、HE4、Fer可提高卵巢疾病诊断的临床价值。
Objective To study the clinical value of the joint detection of 6 serum tumor markers in the diagnosis of ovarian diseases,including carbohydrate antigen125( CA-125),humanepididymisprotein4( HE4),carbohydrate ntigen724( CA-724),carbohydrate antigen199( CA-199),β2-microglobulin( β2-MG) and ferritin( Fer). Methods With chemiluminescence assay,serum levels of CA-125,HE4,CA-72-4,CA19-9,β2-MG and Fer were detected in 33 patients with ovarian cancer( ovarian cancer group),60 patients with ovarian benign disease( benign ovarian disease group) and 54 healthy women( control group) from June 2015 to December 2016,and the differences were statistically significant. Results Serum levels of6 tumor markers were all higher in ovarian cancer group than those in benign ovarian disease group and the control group,and the differences were of statistical significance( P < 0. 05); the positive rate of 6 serum tumor markers in ovarian cancer group were all higher than those in benign ovarian disease group and the control group,and the differences were of statistical significance( P < 0. 05). The positive rate of combined detection with CA125,HE4 and Fer was up to 97. 0%,and that in benign ovarian disease group was up to 30. 0%,which was higher than the positive rate by single assay. Conclusion Fer level is also a preferable assay index in the diagnosis of ovarian cancer,and the combined detection of CA125,HE4 and Fer can improve the diagnostic value of ovarian cancer.
Objective To study the clinical value of the joint detection of 6 serum tumor markers in the diagnosis of ovarian diseases,including carbohydrate antigen125( CA-125),humanepididymisprotein4( HE4),carbohydrate ntigen724( CA-724),carbohydrate antigen199( CA-199),β2-microglobulin( β2-MG) and ferritin( Fer). Methods With chemiluminescence assay,serum levels of CA-125,HE4,CA-72-4,CA19-9,β2-MG and Fer were detected in 33 patients with ovarian cancer( ovarian cancer group),60 patients with ovarian benign disease( benign ovarian disease group) and 54 healthy women( control group) from June 2015 to December 2016,and the differences were statistically significant. Results Serum levels of6 tumor markers were all higher in ovarian cancer group than those in benign ovarian disease group and the control group,and the differences were of statistical significance( P < 0. 05); the positive rate of 6 serum tumor markers in ovarian cancer group were all higher than those in benign ovarian disease group and the control group,and the differences were of statistical significance( P < 0. 05). The positive rate of combined detection with CA125,HE4 and Fer was up to 97. 0%,and that in benign ovarian disease group was up to 30. 0%,which was higher than the positive rate by single assay. Conclusion Fer level is also a preferable assay index in the diagnosis of ovarian cancer,and the combined detection of CA125,HE4 and Fer can improve the diagnostic value of ovarian cancer.
引文
[1]牟永年,崔宏伟,斯琴,等.人附睾蛋白4和糖类抗原125对卵巢癌诊断意义[J].国际检验医学杂志,2016,37(20):2805-2807.
[2]李昌业,黄敏,吴丽,等.妇科疾病中与CA125与炎症相关指标的多因素分析[J].国际检验医学杂志,2016,37(2):171-173.
[3]章涤,王飞,冯阳春,等.血清CA125和HE4联合检测在维吾尔族女性卵巢癌中诊断的研究[J].检验医学与临床,2016,13(4):503-505.
[4]李晋,陈美英,黄敏.HE4检测联合ROMA在女性盆腔良恶性疾病中的鉴别意义[J].实验与检验医学,2017,35(4):560-561.
[5]薛炜,王道霞,唐锦莉,等.2种指标联合检测在卵巢癌早期诊断中的价值[J].检验医学与临床,2016,13(1):73-74.
[6]李一冰,姚秀华,黄山鹰,等.HE4和CA125联合检测对卵巢肿瘤鉴别诊断和病理分型关系研究[J].国际检验医学杂志,2017,38(8):1048-1049.
[7]姚艳霞,洪伟.血清HE4、CA125、和CA72-4检测在卵巢恶性肿瘤诊断中的应用[J].标记免疫分析与临床,2012,19(3):149-152.
[8]白珊珊.CA125、CA72-4、HE4和CEA联合检测在卵巢癌诊断中的应用[J].国际检验医学杂志,2016,37(5):639-641.
[9]欧燕兰,黄丽英,黄千峰,等.联合检测HE4、CA125、和CA19-9在卵巢癌和良性卵巢囊肿的应用价值探讨[J].国际检验医学杂志,2015,36(18):2677-2678.
[10]赵瑞珩.ROC曲线评价血清CA125、CA19-9和CEA对卵巢癌的诊断价值[J].中国实验诊断学,2015,19(11):1954-1955.
[11]何平.健康成人血清β2-微球蛋白参考区间的建立[J].国际检验医学杂志,2011,32(14):1554-1555.
[12]章玉玲,黄迎峰.CA125、HE4、血浆D-二聚体检测在卵巢癌早期诊断中的意义[J].国际检验医学杂志,2017,38(3):347-348.
[13]吕晓梅,陈涛,张小强,等.血清HE4、CA125、CA19-9、CA72-4联合检测对卵巢癌早期诊断的临床价值探讨[J].国际检验医学杂志,2016,37(9):1274-1276.
[14]唐颖,赵长新,李永明,等.联合检测CA125、VEGF-C、β2-MG对卵巢癌淋巴结转移早期诊断的价值[J].国际检验医学杂志,2016,37(14):1930-1932.
[15]郎江明.临床免疫诊断学[M].广州:广东科学技术出版社,2003:382.
[16]丛玉隆.实验检验医学[M].2版.北京:人民卫生出版社,2013:868.
[2]李昌业,黄敏,吴丽,等.妇科疾病中与CA125与炎症相关指标的多因素分析[J].国际检验医学杂志,2016,37(2):171-173.
[3]章涤,王飞,冯阳春,等.血清CA125和HE4联合检测在维吾尔族女性卵巢癌中诊断的研究[J].检验医学与临床,2016,13(4):503-505.
[4]李晋,陈美英,黄敏.HE4检测联合ROMA在女性盆腔良恶性疾病中的鉴别意义[J].实验与检验医学,2017,35(4):560-561.
[5]薛炜,王道霞,唐锦莉,等.2种指标联合检测在卵巢癌早期诊断中的价值[J].检验医学与临床,2016,13(1):73-74.
[6]李一冰,姚秀华,黄山鹰,等.HE4和CA125联合检测对卵巢肿瘤鉴别诊断和病理分型关系研究[J].国际检验医学杂志,2017,38(8):1048-1049.
[7]姚艳霞,洪伟.血清HE4、CA125、和CA72-4检测在卵巢恶性肿瘤诊断中的应用[J].标记免疫分析与临床,2012,19(3):149-152.
[8]白珊珊.CA125、CA72-4、HE4和CEA联合检测在卵巢癌诊断中的应用[J].国际检验医学杂志,2016,37(5):639-641.
[9]欧燕兰,黄丽英,黄千峰,等.联合检测HE4、CA125、和CA19-9在卵巢癌和良性卵巢囊肿的应用价值探讨[J].国际检验医学杂志,2015,36(18):2677-2678.
[10]赵瑞珩.ROC曲线评价血清CA125、CA19-9和CEA对卵巢癌的诊断价值[J].中国实验诊断学,2015,19(11):1954-1955.
[11]何平.健康成人血清β2-微球蛋白参考区间的建立[J].国际检验医学杂志,2011,32(14):1554-1555.
[12]章玉玲,黄迎峰.CA125、HE4、血浆D-二聚体检测在卵巢癌早期诊断中的意义[J].国际检验医学杂志,2017,38(3):347-348.
[13]吕晓梅,陈涛,张小强,等.血清HE4、CA125、CA19-9、CA72-4联合检测对卵巢癌早期诊断的临床价值探讨[J].国际检验医学杂志,2016,37(9):1274-1276.
[14]唐颖,赵长新,李永明,等.联合检测CA125、VEGF-C、β2-MG对卵巢癌淋巴结转移早期诊断的价值[J].国际检验医学杂志,2016,37(14):1930-1932.
[15]郎江明.临床免疫诊断学[M].广州:广东科学技术出版社,2003:382.
[16]丛玉隆.实验检验医学[M].2版.北京:人民卫生出版社,2013:868.